# Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

> **NCT00934895** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 27 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** everolimus
- **DRUG:** abraxane

## Key facts

- **NCT ID:** NCT00934895
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07-15
- **Primary completion:** 2014-01-07
- **Final completion:** 2015-08-12
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Closed early due to slow accrual
- **Last updated:** 2023-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934895, "Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00934895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*